Searchable abstracts of presentations at key conferences in endocrinology

ea0090p318 | Calcium and Bone | ECE2023

Rare association of primary hyperparathyroidism with type 3 multiple autoimmune syndrome

Aycha Ghachem , Elfekih Hamza , Ghada Sabbagh , Saad Ghada , Fatma Barkallah , Hasni Yosra , Chadli Chaieb Molka

Introduction: Primary hyperparathyroidism (PHPT) is most commonly sporadic and in rare circumstances, it can develop as part of multiple endocrine neoplasia (MEN). There are few cases described in the literature reporting an association of PHPT with myasthenia gravis and multiple autoimmune syndrome (MAS). These patients may present only with clinical signs of PHPT making it difficult to suspect the coexistence of MAS. Here, we report the case of type 3 MAS in a woman with PHP...

ea0090ep746 | Pituitary and Neuroendocrinology | ECE2023

Tumor mimicking ampullary carcinoma in a patient with acromegaly

Bnina Molka Ben , Ghada Sabbagh , Elfekih Hamza , Saad Ghada , Fatma Barkallah , Hasni Yosra , Chaieb Molka Chadli

Introduction: Acromegaly is the set of clinical manifestations induced by chronic exposure to an endogenous excess of growth hormone (GH). Most often, acromegaly is related to GH production by a pituitary adenoma. It may be associated with neuroendocrine tumors of the pancreas as part of multiple endocrine neoplasia type 1 (MEN1). Herein, we described a tumor mimicking a carcinoma of the Ampulla of Vater in a patient with acromegaly.Observation: A 54-yea...

ea0090ep1055 | Thyroid | ECE2023

Transient hypothyroidism post radioiodine therapy

Sabbagh Ghada , Elfekih Hamza , Aycha Ghachem , Saad Ghada , Barkallah Fatma , Taieb Ach , Hasni Yosra , Chadli Chaieb Molka

Introduction: Grave’s disease is an autoimmune disorder and is considered the most common cause of hyperthyroidism. Its treatment options include medical therapy, radioactive iodine (RAI), and surgery. RAI is commonly employed for Grave’s disease regarding its efficiency and safety. Definitive hypothyroidism is the main goal of RAI and is typically achieved within the first 3 to 6 months of therapy. Transient hypothyroidism and recurrence of hyperthyroidism after RAI...